Watch BRTX. Know when insiders buy.
One email the day a filing lands. Free.
BRTX
BioRestorative Therapies, Inc.
2.74
+2.59 +1751.35%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $69.8MP/E —DIV YIELD —FCF YIELD —REV TTM $358K −8.5%NET INCOME −$11.1MNET CASH $2.9M52W 0.14 – 2.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $23K | −7.3% | 68.1% | −$3.4M | −$2.2M | — | -0.12 | −$3.8M | — | — | May 14 |
| Q4 2025 · Dec 31derived | $20K | −54.7% | 91.7% | −$3.8M | −$3.2M | — | -0.32 | −$2.4M | $80K | −$2.5M | Mar 26 |
| Q3 2025 · Sep 30 | $12K | −94.9% | 10.4% | −$3.7M | −$3M | — | -0.33 | −$2.9M | $0 | −$2.9M | Nov 12 |
| Q2 2025 · Jun 30 | $303K | +240.4% | 97.1% | −$3.3M | −$2.7M | — | -0.30 | −$2.7M | $0 | −$2.7M | Nov 12 |
| Q1 2025 · Mar 31 | $25K | −28.6% | 88.4% | −$4.8M | −$5.3M | — | -0.64 | −$2.8M | $36K | −$2.8M | May 14 |
| Q4 2024 · Dec 31derived | $43K | +124.4% | 92.3% | −$2.7M | −$1.6M | — | -0.20 | −$2.3M | $12K | −$2.4M | Mar 26 |
| Q3 2024 · Sep 30 | $234K | +660.9% | 92.2% | −$2.3M | −$1.1M | −122.9% | -0.13 | −$1.7M | $58K | −$1.8M | Nov 12 |
| Q2 2024 · Jun 30 | $89K | +38.1% | 92.7% | −$2.5M | −$4M | — | -0.50 | −$1.9M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $35K | — | 100.0% | −$4.1M | −$2.2M | — | -0.33 | −$2.3M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $19K | — | 100.0% | −$3.2M | −$2.3M | — | -0.47 | −$1.6M | $70K | −$1.7M | Mar 28 |
| Q3 2023 · Sep 30 | $31K | — | 100.0% | −$3.1M | $4.8M | — | 0.39 | −$1.2M | $12K | −$1.2M | Nov 12 |
| Q2 2023 · Jun 30 | $65K | — | 100.0% | −$3.1M | −$5.7M | — | -1.47 | −$1.3M | $29K | −$1.3M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $360K | 93.4% | −$15.6M | −$14.2M | -3959.4% | -1.58 | −$10.8M | $116K | −$10.9M | $0 | — |
| FY2024 · to Dec 31 | $401K | 93.0% | −$11.6M | −$9M | -2239.2% | -1.16 | −$8.2M | $106K | −$8.3M | — | — |
| FY2023 · to Dec 31 | $146K | 100.0% | −$15.2M | −$10.4M | -7145.2% | -2.47 | −$6.4M | $171K | −$6.6M | — | — |
| FY2022 · to Dec 31 | $120K | — | −$19M | −$13.2M | -11037.0% | -3.65 | −$5.9M | $265K | −$6.2M | — | — |
| FY2021 · to Dec 31 | $46K | — | −$26.3M | −$44.3M | -96311.5% | -37.30 | −$3.3M | $31K | −$3.4M | — | — |
| FY2020 · to Dec 31 | $77K | — | −$2.8M | −$11.3M | -14639.9% | -28.56 | −$2M | — | — | — | — |
Every number comes from BioRestorative Therapies, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.